This article is more than 5 years old. Information may no longer be current.
Stent trials identify risks, benefits
Click Here to Manage Email Alerts
This month’s focus on interventional cardiology reports the results of several trials on drug-eluting stents.
In a head-to-head comparison of two stents, in-segment late loss was greater with the zotarolimus-eluting stent compared with the sirolimus-eluding stent.
Results of the Endeavor III trial were presented at the Transcatheter Cardiovascular Therapeutics 2005 meeting in Washington.
In another study presented at TCT, the SISR trial, target vessel failure was identified in 12.4% of patients in the sirolimus-eluding stent vs. 21.6% in the brachytherapy group at nine-month follow-up.
Lower event rates overall with drug-eluting stents vs. bare-metal stents were found in the BASKET trial, reported at the European Society of Cardiology Congress 2005.
For more coverage from TCT 2005 and other interventional cardiology news, see the articles listed below.